NCT04731298
Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT.
Phase: Phase 2
Role: Collaborator
Start: May 25, 2021
Completion: Apr 21, 2022